How many institutional investors hold 90572207?

3 tracked institutional investors disclosed a position in 90572207 (BIO RAD LABS INC) in their most recent 13F filing.

Who is the largest institutional holder of 90572207?

Ken Griffin, Citadel Advisors, holds the largest disclosed position in 90572207, valued at $42M.

Where does this 90572207 ownership data come from?

SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.

90572207 — BIO RAD LABS INC

Name: BIO RAD LABS INC (90572207) — Institutional Ownership
Creator: InvestorLens
License: https://www.sec.gov/about/website-policies

Public company

For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About BIO RAD LABS INC (90572207)

BIO RAD LABS INC (90572207) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $42M. Across recent filings, tracked investors recorded 6 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in 90572207

/100

Strong Institutional Accumulation

Added / Increased6

Reduced0

Exited1

BearishBullish

Crowded Trade Score™

How many top investors track 90572207

/100

Emerging Interest

3investors

A small number of top investors own this.

UndiscoveredCrowded

151015+

90572207 Ownership Composition

How BIO RAD LABS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type

Other

100% of tracked value

Institutions

tracked investors

Total Reported

$43.5M

combined 13F value

Other100.0%

Other(3)

100.0%

Tracked investors reporting 90572207

Investor	Firm	Shares	Market value	% of portfolio	As of
Ken Griffin	Citadel Advisors	150.3K	$41.9M	0.01%	Mar 31, 2026
Izzy Englander	Millennium Management	4.1K	$1.1M	0.00%	Mar 31, 2026
Ray Dalio	Bridgewater Associates	1.7K	$469.4K	0.00%	Mar 31, 2026

Ken GriffinMar 31, 2026
Citadel Advisors
Shares
150.3K
Value
$41.9M
% Portfolio
0.01%
Izzy EnglanderMar 31, 2026
Millennium Management
Shares
4.1K
Value
$1.1M
% Portfolio
0.00%
Ray DalioMar 31, 2026
Bridgewater Associates
Shares
1.7K
Value
$469.4K
% Portfolio
0.00%

Recent activity

Investor	Action	Δ %	Current value	Filing date
Izzy Englander	New	—	$11.3M	Feb 17, 2026
Izzy Englander	New	—	$1.1M	May 15, 2026
Ken Griffin	New	—	$41.9M	May 15, 2026
Ray Dalio	New	—	$469.4K	May 15, 2026
Ray Dalio	Sold	-100.00%	$0	Feb 13, 2026
Ken Griffin	New	—	$15.2K	Nov 14, 2025
Ray Dalio	New	—	$3K	Nov 13, 2025

Izzy Englander
New
$11.3MFeb 17, 2026
Izzy Englander
New
$1.1MMay 15, 2026
Ken Griffin
New
$41.9MMay 15, 2026
Ray Dalio
New
$469.4KMay 15, 2026
Ray Dalio
Sold
$0(-100.00%)Feb 13, 2026
Ken Griffin
New
$15.2KNov 14, 2025
Ray Dalio
New
$3KNov 13, 2025

Frequently asked questions

How many institutional investors hold 90572207?: 3 tracked institutional investors disclosed a position in 90572207 (BIO RAD LABS INC) in their most recent 13F filing.
Who is the largest institutional holder of 90572207?: Ken Griffin, Citadel Advisors, holds the largest disclosed position in 90572207, valued at $42M.
Did institutional ownership of 90572207 increase or decrease?: Across recent 13F filings, tracked investors recorded 6 new positions, 0 increased, 0 reduced, and 1 fully exited 90572207.
Where does this 90572207 ownership data come from?: SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.